The Sinopharm-backed oncology drug developer has raised series D1 funding in a round led by China Structural Reform Fund Corporation.

The photonic computing technology spinout of MIT has now pocketed $113m in funding altogether.

The stem cell-transplant technology developer, partly based on Stanford research, is going public through a reverse merger that will give it a $490m market capitalisation.

Roche Venture Fund and Amgen will invest in the stem cell-transplant technology developer through a reverse merger transaction which will give it a $490m market capitalisation.

The Sanofi, Amgen, Alphabet, Novartis and PPD-backed clinical trials software producer is joining forces with publicly listed LifeSci Acquisition II Corp.

The Fosun-backed gene therapy developer had set terms for an offering set to raise between $135m and $149m on the Nasdaq Global Select Market.

Alphabet, Hewlett Packard Enterprise and Lockheed Martin invested in the photonic computing technology developer’s series B round, increasing its total funding to $113m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Advancing Harvard Medical School research, Dyno Therapeutics has raised $100m to advance its gene therapies based on AAV.